LA JOLLA, Calif., Sept. 12, 2019 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs, today announced that Nature
Communications has published an article entitled,
"Discovery and preclinical evaluation of anti-miR-17
oligonucleotide RGLS4326 for the treatment of polycystic kidney
disease." The article highlights preclinical research that
identifies RGLS4326, a first-in-class anti-miR-17 oligonucleotide,
as a potential disease-modifying treatment for autosomal dominant
polycystic kidney disease (ADPKD) and can be found on-line
at http://www.nature.com/ncomms.
"Our successful collaboration between Regulus scientists and
Dr. Vishal Patel and his team at UT Southwestern
Medical Center represents a major advance in our understanding of
the unique mechanism of action of RGLS4326. We believe this
collaborative effort has demonstrated that targeting miR-17 may
provide therapeutic benefit for ADPKD patients," said Jay Hagan, CEO of Regulus.
About ADPKD
ADPKD, caused by the mutations in the PKD1 or PKD2 genes, is
among the most common human monogenic disorders and a leading cause
of end-stage renal disease. The disease is characterized by the
development of multiple fluid filled cysts primarily in the
kidneys, and to a lesser extent in the liver and other organs.
Excessive kidney cyst cell proliferation, a central pathological
feature, ultimately leads to end-stage renal disease in
approximately 50% of ADPKD patients by age 60.
About RGLS4326
RGLS4326 is a novel oligonucleotide designed to inhibit miR-17
and designed to preferentially target the kidney. Preclinical
studies with RGLS4326 have demonstrated direct regulation of PKD1
and PKD2 in human ADPKD cyst cells, a reduction in kidney cyst
formation, improved kidney weight/body weight ratio, decreased cyst
cell proliferation, and preserved kidney function in mouse models
of ADPKD.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus maintains its
corporate headquarters in La Jolla,
CA.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the completion of
preclinical and clinical activities concerning the RGLS4326
program, including statements regarding the sufficiency of the data
resulting from the ongoing or planned preclinical studies required
to recommence the clinical studies and the timing of preclinical
and clinical activities. Because such statements are subject
to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of
events could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, risks associated
with the process of discovering, developing and commercializing
drugs that are safe and effective for use as human therapeutics and
in the endeavor of building a business around such drugs, and
feedback from the FDA. These and other risks are described in
additional detail in Regulus' filings with the Securities and
Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. Regulus undertakes no obligation to update such statements to
reflect events that occur or circumstances that exist after the
date on which they were made.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regulus-therapeutics-announces-publication-in-nature-communications-identifying-rgls4326-as-a-potential-promising-treatment-for-adpkd-300916668.html
SOURCE Regulus Therapeutics Inc.